Responses of all MM samples to targeted mutBRAF inhibitor dabrafenib, downstream MEK1 inhibitor trametinib, or the clinically relevant co-inhibition remained very low, 10–20%, irrespective of the intrinsic BRAF/NRAS or p53 mutation status (Fig. S1). This evidence concerns the gene MAP2K1 and Miyoshi myopathy.